65,437 trials
Asthma, Bronchial
Primary: Asthma Control Measured With Asthma Control Test (ACT) — 20.49; 18.23 units on a scale
Spinal Cord Injury
Primary: Conduct pre-and Post-training Assessments of Behavioral Outcomes Using Wolf Motor Function Test and Jebsen Taylor Hand Function Test to Measure Upper Extremity Function…
Multimorbidity
Primary: Number of Participants Experiencing Repeat ED Use — 64; 59 Participants
Asthma
Primary: Mean Change From Baseline in Total Asthma Symptom Score (Daytime Plus Night Time) at the End of the Treatment Period 1 (TP1) — -3.01; -3.97 Scores on a scale — p=0.206
Dry Eye Syndrome
Primary: Change From Baseline in Total Ocular Surface Staining (TOSS) Score at Day 28 — -1.19; -0.94 units on a scale
Knee Osteoarthritis
Primary: Knee Adduction Moment at Baseline — 0.376; 0.342 Nm/(kg-m)
Sleep · Pain · Anxiety
Primary: Change From Baseline in PROMIS Composite T-Score at 3-Month Follow-up — 3.48; 2.38 T-score — p=0.165
Influenza
Primary: Titers for Serum H5N1 Haemagglutination-inhibition (HI) Antibodies — 739.5; 621.7 Titers
Dry Eye
Primary: Length of Retention — 6; 6 months
Healthy
Primary: Pharmacokinetic Parameters (Area Under the Plasma Concentration Versus Time Curve (AUC)) — 5277.01; 6726.99 nanogram*hour per millilitre (ng*h/mL) — p=0.0002
Lumbar Spinal Stenosis
Primary: Utilization of ESI — 3.6; 3.3 number of ESI between 18-24 months
Osteoporosis
Primary: Weighted Average Inhibition (WAI) of Urine Aminoterminal Crosslinked Telopeptide of Type I Collagen (u-NTx/Cr) After Administration of Odanacatib 50 mg or Placebo Qw for…
Bipolar Disorder · Schizophrenia
Primary: Positive Detection Accuracy — 94 percentage of observed ingestions
Dementia
Primary: Change in Quality of Life — 2.8; 2.8 units on a scale
Sarcoma, Kaposi
Primary: Overall Response Rate (ORR) of Six Cycles of Liposomal Doxorubicin Combined With Bevacizumab in Patients With Advanced KS. — 50; 67 percentage of participants